Rutul Shah serves as the Chief Operating Officer at Precigen, Inc., a biotechnology company focused on developing advanced gene and cell therapies. With a robust background in biotechnology and pharmaceuticals, Shah has been instrumental in steering Precigen towards significant growth and innovation. Prior to joining Precigen, Shah held various leadership positions in the industry, including roles at Intrexon Corporation, where he honed his skills in operations and strategic planning. At Precigen, Shah's role as COO involves overseeing the company's day-to-day operations and ensuring the seamless execution of its strategic initiatives. His leadership has been pivotal in advancing the company's pipeline of therapies, which target a range of diseases from cancer to infectious diseases. Under his guidance, Precigen has made notable progress in clinical trials and has strengthened its position in the competitive biotech landscape. Shah's strategic vision and operational expertise have been key drivers in positioning Precigen as a leader in the gene and cell therapy space. Shah's achievements extend beyond his operational role at Precigen. He is recognized in the industry for his contributions to the advancement of biotechnology, having been involved in numerous successful product launches and partnerships. His ability to navigate complex regulatory environments and drive innovation has earned him respect among peers and stakeholders alike. Shah's commitment to improving patient outcomes through cutting-edge therapies continues to inspire his work at Precigen, where he remains dedicated to transforming the future of medicine.